Genesis Biopharma Inc. is a biotechnology company developing targeted cancer therapies. The company is working on a targeted anti-CD55 cancer therapeutic, whose parent antibody has been used extensively in humans as a cancer diagnostic. The parent antibody has been shown to be safe and highly selective in identifying various tumors including colorectal, breast, gastric and lung cancers.

The company today announced that it has named Martin Schroeder to its Board of Directors. Mr. Schroeder is a business consultant with more than 30 years of experience advising healthcare companies with regard to corporate strategy, strategic partnerships, marketing and business development, competitive positioning, and mergers and acquisitions.

Mr. Schroeder is currently executive vice-president and managing director of the Emmes Group Inc., a strategic business consulting firm, and is responsible for its West Coast and international practices. He has also held a number of industry management and executive positions. These include chairman, president and CEO of AMS Inc., a venture capital-backed molecular genetics company. Mr. Schroeder was also a visiting scientist at the US Department of Agriculture.

Genesis Biopharma had already been working with Mr. Schroeder for the past several months. He has been instrumental in the development and execution of the company’s autologous cell therapy strategy and in the formation of its new Scientific and Medical Advisory Board. He is expected to be a key player in the months ahead with the commercialization of Genesis Biopharma’s cancer therapy product, Contego, which is to be used for the treatment of metastatic melanoma.

For additional information on Genesis Biopharma, please visit the company’s website at www.genesis-biopharma.com